[A17-08] Secukinumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V (new scientific findings)
Last updated 01.06.2017
Project no.:
A17-08
Commission:
Commission awarded on 01.03.2017 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Skin and hair
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Federal Joint Committee (G-BA)
2017-08-17 A G-BA decision was published.